Bridgeway Capital Management’s Charles River Laboratories CRL Stock Holding History

Bridgeway Capital Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-7,400	Closed	-$1.53M	–	1276
2024 Q2	$1.53M	Sell	7,400 -20,850	-74%	-$4.72M	0.04%	579
2024 Q1	$7.65M	Sell	28,250 -15,300	-35%	-$3.65M	0.16%	195
2023 Q4	$10.3M	Sell	43,550 -1,750	-4%	-$344K	0.22%	129
2023 Q3	$8.88M	Sell	45,300 -8,075	-15%	-$1.66M	0.22%	133
2023 Q2	$11.2M	Sell	53,375 -4,000	-7%	-$796K	0.27%	90
2023 Q1	$11.6M	Sell	57,375 -6,900	-11%	-$1.56M	0.31%	63
2022 Q4	$14M	Buy	64,275 +2,925	+5%	+$639K	0.36%	35
2022 Q3	$12.1M	Sell	61,350 -24,750	-29%	-$5.34M	0.32%	48
2022 Q2	$18.4M	Buy	+86,100	New	+$21M	0.42%	16

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Meritage Group San Francisco, California $2.65B AUM 6.3% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Eminence Capital New York $4.36B AUM 3.1% 1-Year Est. Return

Bridgeway Capital Management's CRL Position: Q3 2024 in Review

Bridgeway Capital Management sold out of Charles River Laboratories (CRL) in Q3 2024, closing a stake of 7,400 shares — an estimated $1.53M sold.

Bridgeway Capital Management first reported a position in CRL in Q2 2022 and held it in 9 quarters. The position peaked at $18.4M in Q2 2022. 627 funds tracked by Wall St. Rank hold CRL as of Q3 2024.

Bridgeway Capital Management reported no remaining Charles River Laboratories position as of Q3 2024 after selling out during the quarter.
Bridgeway Capital Management sold 7,400 Charles River Laboratories shares in Q3 2024, an estimated $1.53M.
Bridgeway Capital Management first reported a position in Charles River Laboratories in Q2 2022 and held it in 9 quarters.
Bridgeway Capital Management's Charles River Laboratories position peaked at $18.4M in Q2 2022.
627 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2024.

Based on Bridgeway Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.